



**DCAT**  
**TOP**  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

**1. [Pfizer to Sell Hospira Infusion Systems Business for \\$1 Billion to ICU Medical](#)**

Pfizer has agreed to sell its Hospira Infusion Systems business for \$1 billion in cash and stock to ICU Medical, a San Clemente, California-based medical devices company. The Hospira Infusion Systems business includes IV pumps, solutions, and devices. Pfizer acquired the business as part of its \$17 billion acquisition of Hospira in 2015. [Read More](#)

**2. [Teva To Sell Actavis' UK, Ireland Assets and Operations for \\$761 Million](#)**

Teva Pharmaceutical Industries has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited, a generic pharmaceutical company and a subsidiary of Ahmedabad, India-based Intas Pharmaceuticals, for an agreed value of £603 million (\$761 million), subject to final approval from the European Commission (EC). The divestment is part of EC requirements in approving Teva's \$40.5 billion acquisition of the generics business of Allergan (including of Actavis) earlier this year. [Read More](#)

**3. [Mylan Agrees to \\$465 Million EpiPen Settlement with US Gov't](#)**

Mylan has agreed to a \$465 million settlement with the US Department of Justice and other government agencies to resolve questions about whether its EpiPen Auto-Injector was properly classified for the Medicaid Drug Rebate Program with the Centers for Medicaid and Medicare Services. The settlement comes amid increased attention to the pricing of the product and subsequent moves by the company to address these concerns. [Read More](#)

**4. [AstraZeneca, Allergan Partner for Crohn's Disease Drug in Deal Worth Up to \\$1.52 Billion](#)**

AstraZeneca, through MedImmune, its biologics research and development arm, has entered into a licensing agreement with Allergan for the global rights to MedImmune's anti-inflammatory candidate, MEDI2070, an interleukin-23 monoclonal antibody in a Phase IIb clinical trial for moderate-to-severe Crohn's disease, in a deal worth up to \$1.52 billion. [Read More](#)

**5. [Medigene, Bluebird Bio in Cancer Pact Worth Over \\$1.15 Billion](#)**

Medigene, a Martinsried, Germany-based biotechnology company focused on personalized T-cell-based immunotherapies, has entered into a R&D collaboration and licensing agreement with bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene therapy company, for development of T-cell receptor immunotherapies against four oncology targets in a deal valued up to \$1.15 billion. [Read More](#)

**6. [Genentech, Hanmi Form Cancer-Drug Pact Worth Over \\$910 Million](#)**

Roche's Genentech has signed an exclusive development and license agreement with Hanmi Pharmaceutical, a Seoul, South Korea-based pharmaceutical company, to develop and commercialize Hanmi's pan-RAF inhibitor, HM95573, currently in Phase I clinical development for treating solid tumors in a deal worth up to \$910 million. [Read More](#)

**7. [EMA to Review Samsung Bioepis' Herceptin Biosimilar](#)**

The European Medicines Agency has accepted for review a marketing authorization application from Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, for a biosimilar candidate referencing Herceptin (trastuzumab), Roche's monoclonal antibody for treating early breast cancer, metastatic breast cancer, and metastatic gastric cancer. Herceptin is one of Roche's leading products with global 2015 sales of CHF 6.5 billion (\$6.7 billion). [Read More](#)

## 8. [Teva, Celltrion Form Biosimilars Partnership](#)

Teva Pharmaceutical Industries has formed an exclusive partnership with Celltrion, an Incheon, Korea-based life sciences company, and Celltrion Healthcare to commercialize two of Celltrion's monoclonal antibody biosimilar candidates in the US and Canada: one referencing Roche's Rituxan (rituximab) and the other Roche's Herceptin (trastuzumab). Rituxan and Herceptin are two of Roche's leading products, with 2015 sales of CHF 5.6 billion (\$5.7 billion) and CHF 6.5 billion (\$6.7 billion), respectively. [Read More](#)

## 9. [Takeda, Crescendo Biologics in Therapeutics Pact Worth Up to \\$790 Million](#)

Takeda Pharmaceutical has formed a collaboration with Crescendo Biologics, a Cambridge, UK-based biopharmaceutical company, to discover, develop, and commercialize Humabody-based cancer therapeutics in a deal worth up to \$790 million. Humabody products are a class of small protein therapeutics based on fully human variable heavy domain building blocks. [Read More](#)

## 10. [GSK Names New CEO of Consumer Healthcare](#)

GlaxoSmithKline (GSK) has appointed Brian McNamara as CEO of GSK's consumer healthcare division effective immediately. He succeeds Emma Walmsley, who was recently appointed GSK CEO designate and who will succeed Andrew Witty as GSK CEO upon his retirement next year. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)